Buprenorphine
A partial opioid agonist used both for the treatment of opioid use disorder and for moderate-to-severe pain management. At lower doses, it suppresses opioid cravings and withdrawal symptoms while reducing the euphoric effects of other opioids. Its ceiling effect on respiratory depression makes it safer in overdose compared to full opioid agonists.
Moleküler Ağırlık
467,6430 g/mol
LogP
5,00
TPSA
62,20 Ų
Lipinski RO5
Geçer
Terapötik Alanlar
İlaç Sınıfları
Etki Mekanizması
Partial mu-opioid receptor agonist and kappa antagonist with high receptor affinity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Partial mu-opioid receptor agonist and kappa antagonist with high receptor affinity.
2D Yapı
Cite this structure
Embed this structure
SMILES
CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
InChI
InChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29+/m1/s1
Molecular Formula
C29H41NO4
HBD / HBA
2 / 5
Döndürülebilir Bağlar
5
Ağır Atomlar
34
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
A partial opioid agonist used both for the treatment of opioid use disorder and for moderate-to-severe pain management. At lower doses, it suppresses opioid cravings and withdrawal symptoms while reducing the euphoric effects of other opioids. Its ceiling effect on respiratory depression makes it safer in overdose compared to full opioid agonists.
Partial mu-opioid receptor agonist and kappa antagonist with high receptor affinity.
Key pharmacokinetic parameters for Buprenorphine: Half-life: 24-42 hours.
Yes, Buprenorphine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
Related Drugs
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL511142. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 644073. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="buprenorphine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/buprenorphine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/buprenorphine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/buprenorphine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="buprenorphine"></drugfyi-drug>